FDA & Government News

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

Share

  • 1

    Lebrikizumab demonstrates effectiveness for pediatric atopic dermatitis.

  • 2

    63% achieved a 75% reduction in EASI.

  • 3

    Trial included 363 children aged 6 months to 18 years.

  • 4

    Safety profile similar to adults with common issues being upper respiratory infections.

  • 5

    Significant itch relief reported.

  • 6

    Lilly seeks potential label expansion approval.

  • 7

    Long-term study, ADorable-2, follows patients for 52 weeks.

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

Sunscreen Costs Vary Up to 36-Fold

Economic analysis finds large differences in the annual cost of recommended sunscreen use depending on product price and clothing-based sun protection strategies

HS Linked to Higher Self-Harm, Suicide Risk

Prior self-harm episodes and nonviolent methods are more common among HS patients who die by suicide, new research finds.

Dual-Frequency Radiofrequency for Facial Laxity?

Investigators report high 90-day response rates with no persistent adverse events.